PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Apremilast - Psoriasis

PAD Profile : Apremilast - Psoriasis

Keywords :
Biologic, NICE, immunosuppressant, phosphodiesterase type-4 inhibitor, PDE4 inhibitorDMARD, bDmard, Disease modulating, Dermatology, biosimilar
Brand Names Include :
Otezla

Traffic Light Status

Status 1 of 2.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
Psoriasis - High cost immunomodulator treatment pathway - October 23.pdf
31 October 2026
NICE Technology Appraisal
NICE TA419 Apremilast for treating moderate to severe plaque psoriasis
Evidence Review
Apremilast for treating moderate to severe plaque - Evidence Review Feb-17

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

01 February 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Apremilast as a treatment option for moderate to severe plaque psoriasis in line with NICE TA419 (23rd November 2016). Apremilast is a payment by results excluded drug which will be considered RED on the traffic light system. The current psoriasis treatment pathway is available on the prescribing advisory database.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More